Tracer library / [131I]I-WS03

[131I]I-WS03

Also written as [I-131]I-WS03

Radionuclide: I-131 t½ 11549 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Breast cancer Preclinical only, no clinical indication yet

What it is

Compound class: Dual-modality radio-fluorescent probe (benzothiazole-FITC conjugate)
Target / mechanism: Estrogen receptor alpha (ERα) binding PMID 42519085
Clinical application: Breast cancer cell imaging (in vitro, MCF-7 and MDA-MB-231 cells) PMID 42519085
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	—	—	93.55 ± 0.50%	WS03	42519085 2026 RSC Adv The fluorescent probes BNF03 and WS03 were labeled with a β-/γ radionuclide (iodine-131) via direct radioiodination at low pH (pH = 4, using glacial acetic acid).

Need this precursor?We can point you to suppliers for [131I]I-WS03, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 42519085. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 39 from PMID 42519085: 'Two hybrid probes [131I]I-BNF03 and [131I]I-WS03, were successfully synthesised and evaluated in vitro.'.